Severe bronchospasm associated with rituximab for refractory Churg–Strauss syndrome
- 13 March 2009
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 68 (4), 606
- https://doi.org/10.1136/ard.2008.093773
Abstract
Rituximab is now used to control antineutrophil cytoplasm antibody (ANCA)-associated vasculitides, eg, Wegener’s granulomatosis.1 2 In Churg–Strauss syndrome (CSS), a small-vessel systemic vasculitis with asthma and eosinophilia, 39% of patients have ANCA.3 4 Rituximab could be effective in ANCA-associated vasculitides, even if ANCA are not present at the time of prescription, because B lymphocytes also play a role as antigen-presenting cells and can modulate the immune response in another way than targeting antibody production. Therapy-refractory CSS5 was successfully treated with rituximab in three patients.6–8 We would like to draw attention to the potential risk of rituximab-associated bronchospasm, by reporting …Keywords
This publication has 8 references indexed in Scilit:
- Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 productionRheumatology, 2008
- EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitisAnnals Of The Rheumatic Diseases, 2007
- Rituximab in Churg-Strauss syndromeAnnals Of The Rheumatic Diseases, 2006
- Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndromeAnnals Of The Rheumatic Diseases, 2006
- Antineutrophil Cytoplasmic Antibodies and the Churg–Strauss SyndromeAnnals of Internal Medicine, 2005
- Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg‐Strauss syndromeArthritis & Rheumatism, 2005
- Advances in the management of hereditary medullary thyroid cancerJournal of Internal Medicine, 2004
- Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable ToxicityJournal of Clinical Oncology, 2001